Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1983 2
1984 6
1985 39
1986 13
1987 17
1988 14
1989 18
1990 16
1991 31
1992 12
1993 4
1994 6
1995 3
1996 7
1997 1
1998 1
1999 2
2000 3
2001 4
2002 2
2003 3
2005 3
2006 4
2007 2
2008 4
2009 3
2010 6
2011 4
2012 4
2013 2
2014 5
2015 4
2016 4
2017 3
2018 2
2019 3
2020 1
2021 2
2022 6
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Results by year

Filters applied: . Clear all
Page 1
Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.
Holland TL, Cosgrove SE, Doernberg SB, Jenkins TC, Turner NA, Boucher HW, Pavlov O, Titov I, Kosulnykov S, Atanasov B, Poromanski I, Makhviladze M, Anderzhanova A, Stryjewski ME, Assadi Gehr M, Engelhardt M, Hamed K, Ionescu D, Jones M, Saulay M, Smart J, Seifert H, Fowler VG Jr; ERADICATE Study Group. Holland TL, et al. N Engl J Med. 2023 Oct 12;389(15):1390-1401. doi: 10.1056/NEJMoa2300220. Epub 2023 Sep 27. N Engl J Med. 2023. PMID: 37754204 Clinical Trial.
METHODS: In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg intravenously every 6 hours for 8 days and every 8 hours thereafter, or dapto …
METHODS: In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus bacteremia were randomly assig …
Aztreonam--an overview.
Hopefl AW. Hopefl AW. Drug Intell Clin Pharm. 1985 Mar;19(3):171-5. Drug Intell Clin Pharm. 1985. PMID: 3884302 Review.
Aztreonam is the first synthetic monobactam to undergo clinical studies in the U.S. ...Aztreonam may be an alternate to aminoglycoside therapy, with the advantage of not being nephrotoxic....
Aztreonam is the first synthetic monobactam to undergo clinical studies in the U.S. ...Aztreonam may be an alternate to aminog …
Heterogeneity of treatment response in bronchiectasis clinical trials.
Sibila O, Laserna E, Shoemark A, Perea L, Bilton D, Crichton ML, De Soyza A, Boersma WG, Altenburg J, Chalmers JD. Sibila O, et al. Eur Respir J. 2022 May 5;59(5):2100777. doi: 10.1183/13993003.00777-2021. Print 2022 May. Eur Respir J. 2022. PMID: 34675045 Free article. Clinical Trial.
METHODS: We evaluated treatment response in three randomised clinical trials that evaluated mucoactive therapy (inhaled mannitol), an oral anti-inflammatory/antibiotic (azithromycin) and an inhaled antibiotic (aztreonam). Treatment response was defined by an absence of exa …
METHODS: We evaluated treatment response in three randomised clinical trials that evaluated mucoactive therapy (inhaled mannitol), an oral a …
Randomized clinical trial of aztreonam and aminoglycoside antibiotics in the treatment of serious infections caused by gram-negative bacilli.
DeMaria A Jr, Treadwell TL, Saunders CA, Porat R, McCabe WR. DeMaria A Jr, et al. Antimicrob Agents Chemother. 1989 Aug;33(8):1137-43. doi: 10.1128/AAC.33.8.1137. Antimicrob Agents Chemother. 1989. PMID: 2679368 Free PMC article. Clinical Trial.
A total of 43 evaluable patients with 47 infected sites were treated with aztreonam, and 41 evaluable patients were treated with aminoglycosides for 43 infections. Of patients treated with aztreonam, 17 were bacteremic, as were 12 of those treated with aminoglycosid …
A total of 43 evaluable patients with 47 infected sites were treated with aztreonam, and 41 evaluable patients were treated with amin …
Clinical experience with aztreonam for treatment of infections in children.
Stutman HR. Stutman HR. Rev Infect Dis. 1991 May-Jun;13 Suppl 7:S582-5. doi: 10.1093/clinids/13.supplement_7.s582. Rev Infect Dis. 1991. PMID: 2068462 Review.
The in vitro activity, pharmacokinetics, bactericidal activity, and tissue penetration of aztreonam suggest that it may play a role in therapy for serious gram-negative bacterial infections in children. ...Aztreonam yielded clinical results comparable to those of co …
The in vitro activity, pharmacokinetics, bactericidal activity, and tissue penetration of aztreonam suggest that it may play a role i …
The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF).
Frost F, Young GR, Wright L, Miah N, Smith DL, Winstanley C, Walshaw MJ, Fothergill JL, Nazareth D. Frost F, et al. J Cyst Fibros. 2021 Nov;20(6):994-1002. doi: 10.1016/j.jcf.2020.12.012. Epub 2021 Jan 7. J Cyst Fibros. 2021. PMID: 33358119 Free article. Clinical Trial.
BACKGROUND: The objective of this study was to explore the clinical and microbiological outcomes associated with substituting inhaled aztreonam lysine for an intravenous antibiotic in the treatment of acute pulmonary exacerbations of CF. ...Over the course of two exacerbat …
BACKGROUND: The objective of this study was to explore the clinical and microbiological outcomes associated with substituting inhaled azt …
Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.
Lodise TP, O'Donnell JN, Balevic S, Liu X, Gu K, George J, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG Jr, Wall A, Wiegand K, Chambers HF; Antibacterial Resistance Leadership Group. Lodise TP, et al. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093622. doi: 10.1128/aac.00936-22. Epub 2022 Nov 17. Antimicrob Agents Chemother. 2022. PMID: 36394326 Free PMC article. Clinical Trial.
Scant pharmacokinetic (PK) data are available on ceftazidime-avibactam (CZA) and aztreonam (ATM) in combination, and it is unknown if CZA-ATM exacerbates alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevations relative to ATM alone. ...
Scant pharmacokinetic (PK) data are available on ceftazidime-avibactam (CZA) and aztreonam (ATM) in combination, and it is unknown if …
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients.
Smith PF, Ballow CH, Booker BM, Forrest A, Schentag JJ. Smith PF, et al. Clin Ther. 2001 Aug;23(8):1231-44. doi: 10.1016/s0149-2918(01)80103-x. Clin Ther. 2001. PMID: 11558860 Clinical Trial.
OBJECTIVE: This study evaluated the relationship between serum pharmacokinetics, pharmacodynamics, pathogen susceptibility, and clinical outcomes in patients receiving aztreonam or tobramycin monotherapy. METHODS: The case-report forms of hospitalized patients who received …
OBJECTIVE: This study evaluated the relationship between serum pharmacokinetics, pharmacodynamics, pathogen susceptibility, and clinical out …
Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Brogden RN, Heel RC. Brogden RN, et al. Drugs. 1986 Feb;31(2):96-130. doi: 10.2165/00003495-198631020-00002. Drugs. 1986. PMID: 3512234 Review.
Aztreonam (azthreonam; SQ 26,776) is the first member of a new class of beta-lactam antibiotics, the monobactams. ...Aztreonam is inactive against Gram-positive aerobic bacteria and anaerobes, including Bacteroides fragilis. ...
Aztreonam (azthreonam; SQ 26,776) is the first member of a new class of beta-lactam antibiotics, the monobactams. ...Aztreonam …
Aztreonam therapy for serious gram-negative bacillary infections.
Cone LA, Woodard DR. Cone LA, et al. Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S794-802. doi: 10.1093/clinids/7.supplement_4.s794. Rev Infect Dis. 1985. PMID: 3909339 Review.
Fifty episodes of gram-negative bacillary infection, including episodes of bacteremia, pneumonia, and skin and soft tissue, complicated urinary tract, and abdominal infections, were treated with aztreonam. Eighty-eight percent of patients were cured of their infection, inc …
Fifty episodes of gram-negative bacillary infection, including episodes of bacteremia, pneumonia, and skin and soft tissue, complicated urin …
265 results